Clinical Trial Update: Effects of Repeat Dosing of GSK1521498 [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating repeat dosing of GSK1521498 in obesity has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• GSK1521498 (GSK1521498)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Obesity | Phase 1 | Status: COMPLETED